FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2017-06, Vol.35 (S2), p.141-142 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 142 |
|---|---|
| container_issue | S2 |
| container_start_page | 141 |
| container_title | Hematological oncology |
| container_volume | 35 |
| creator | Gressin, R. Daguindau, N. Tempescul, A. Moreau, A. Carras, S. Cartron, G. Schmitt, A. Houot, R. Dartigeas, C. Pignon, J. Corm, S. Bannos, A. Mounier, C. Dupuis, J. Macro, M. Fleury, J. Jardin, F. Karlin, L. Damaj, G. Feugier, P. Fornecker, L. Chabrot, C. Ysebaert, I. Callanan, M. Le Gouill, S. |
| description | |
| doi_str_mv | 10.1002/hon.2437_131 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1906638434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1906638434</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1921-6174e3e403a8c6413d51c2c9f2c1e83c0cc5af9e9212aacb4535ece38ac8e953</originalsourceid><addsrcrecordid>eNp9kV1LwzAYhYMoOD_u_AEveGs1H23X4lXtsjaQtSPNBrsKNWa4oU5bRfxX_kQzp156Fch5zjkvHITOCL4kGNOr-83TJQ3Z0BBG9tCA4DQNCI7TfTTAdJgEmDJ6iI76fo2x13AyQJ9joRoNUlQctOKZnvBKw80CdMlBiZv5CBQvhP8FLkUudAOlKErIvUPkmYSsGsGkljyfyUx5tpnWVeOtmebNtzhVtayrgo-gmam5mHuP2IaNuJILmOQSppkWvrW5hrGovOxDZtIX1WNoQS6aDApVz6b-PpHJE3SwbB96d_rzHiM95jovA1kX24MCS1JKgpgMQ8dciFmb2Dgk7C4iltp0SS1xCbPY2qhdps6ztG3tbRixyFnHktYmLo3YMTrfxT53m5c317-a9eate_KNhqQ4jlkSstBTFzvKdpu-79zSPHerx7b7MASb7STGT2J-J_F4tMPfVw_u41_WlHX15_sCZ3OBfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1906638434</pqid></control><display><type>article</type><title>FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL</title><source>Access via Wiley Online Library</source><creator>Gressin, R. ; Daguindau, N. ; Tempescul, A. ; Moreau, A. ; Carras, S. ; Cartron, G. ; Schmitt, A. ; Houot, R. ; Dartigeas, C. ; Pignon, J. ; Corm, S. ; Bannos, A. ; Mounier, C. ; Dupuis, J. ; Macro, M. ; Fleury, J. ; Jardin, F. ; Karlin, L. ; Damaj, G. ; Feugier, P. ; Fornecker, L. ; Chabrot, C. ; Ysebaert, I. ; Callanan, M. ; Le Gouill, S.</creator><creatorcontrib>Gressin, R. ; Daguindau, N. ; Tempescul, A. ; Moreau, A. ; Carras, S. ; Cartron, G. ; Schmitt, A. ; Houot, R. ; Dartigeas, C. ; Pignon, J. ; Corm, S. ; Bannos, A. ; Mounier, C. ; Dupuis, J. ; Macro, M. ; Fleury, J. ; Jardin, F. ; Karlin, L. ; Damaj, G. ; Feugier, P. ; Fornecker, L. ; Chabrot, C. ; Ysebaert, I. ; Callanan, M. ; Le Gouill, S.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2437_131</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Geriatrics ; Older people ; Patients ; Survival</subject><ispartof>Hematological oncology, 2017-06, Vol.35 (S2), p.141-142</ispartof><rights>2017 The Authors. published by John Wiley & Sons, Ltd.</rights><rights>2017 The Authors. Hematological Oncology published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1921-6174e3e403a8c6413d51c2c9f2c1e83c0cc5af9e9212aacb4535ece38ac8e953</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.2437_131$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.2437_131$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Gressin, R.</creatorcontrib><creatorcontrib>Daguindau, N.</creatorcontrib><creatorcontrib>Tempescul, A.</creatorcontrib><creatorcontrib>Moreau, A.</creatorcontrib><creatorcontrib>Carras, S.</creatorcontrib><creatorcontrib>Cartron, G.</creatorcontrib><creatorcontrib>Schmitt, A.</creatorcontrib><creatorcontrib>Houot, R.</creatorcontrib><creatorcontrib>Dartigeas, C.</creatorcontrib><creatorcontrib>Pignon, J.</creatorcontrib><creatorcontrib>Corm, S.</creatorcontrib><creatorcontrib>Bannos, A.</creatorcontrib><creatorcontrib>Mounier, C.</creatorcontrib><creatorcontrib>Dupuis, J.</creatorcontrib><creatorcontrib>Macro, M.</creatorcontrib><creatorcontrib>Fleury, J.</creatorcontrib><creatorcontrib>Jardin, F.</creatorcontrib><creatorcontrib>Karlin, L.</creatorcontrib><creatorcontrib>Damaj, G.</creatorcontrib><creatorcontrib>Feugier, P.</creatorcontrib><creatorcontrib>Fornecker, L.</creatorcontrib><creatorcontrib>Chabrot, C.</creatorcontrib><creatorcontrib>Ysebaert, I.</creatorcontrib><creatorcontrib>Callanan, M.</creatorcontrib><creatorcontrib>Le Gouill, S.</creatorcontrib><title>FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL</title><title>Hematological oncology</title><subject>Geriatrics</subject><subject>Older people</subject><subject>Patients</subject><subject>Survival</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kV1LwzAYhYMoOD_u_AEveGs1H23X4lXtsjaQtSPNBrsKNWa4oU5bRfxX_kQzp156Fch5zjkvHITOCL4kGNOr-83TJQ3Z0BBG9tCA4DQNCI7TfTTAdJgEmDJ6iI76fo2x13AyQJ9joRoNUlQctOKZnvBKw80CdMlBiZv5CBQvhP8FLkUudAOlKErIvUPkmYSsGsGkljyfyUx5tpnWVeOtmebNtzhVtayrgo-gmam5mHuP2IaNuJILmOQSppkWvrW5hrGovOxDZtIX1WNoQS6aDApVz6b-PpHJE3SwbB96d_rzHiM95jovA1kX24MCS1JKgpgMQ8dciFmb2Dgk7C4iltp0SS1xCbPY2qhdps6ztG3tbRixyFnHktYmLo3YMTrfxT53m5c317-a9eate_KNhqQ4jlkSstBTFzvKdpu-79zSPHerx7b7MASb7STGT2J-J_F4tMPfVw_u41_WlHX15_sCZ3OBfw</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Gressin, R.</creator><creator>Daguindau, N.</creator><creator>Tempescul, A.</creator><creator>Moreau, A.</creator><creator>Carras, S.</creator><creator>Cartron, G.</creator><creator>Schmitt, A.</creator><creator>Houot, R.</creator><creator>Dartigeas, C.</creator><creator>Pignon, J.</creator><creator>Corm, S.</creator><creator>Bannos, A.</creator><creator>Mounier, C.</creator><creator>Dupuis, J.</creator><creator>Macro, M.</creator><creator>Fleury, J.</creator><creator>Jardin, F.</creator><creator>Karlin, L.</creator><creator>Damaj, G.</creator><creator>Feugier, P.</creator><creator>Fornecker, L.</creator><creator>Chabrot, C.</creator><creator>Ysebaert, I.</creator><creator>Callanan, M.</creator><creator>Le Gouill, S.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201706</creationdate><title>FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL</title><author>Gressin, R. ; Daguindau, N. ; Tempescul, A. ; Moreau, A. ; Carras, S. ; Cartron, G. ; Schmitt, A. ; Houot, R. ; Dartigeas, C. ; Pignon, J. ; Corm, S. ; Bannos, A. ; Mounier, C. ; Dupuis, J. ; Macro, M. ; Fleury, J. ; Jardin, F. ; Karlin, L. ; Damaj, G. ; Feugier, P. ; Fornecker, L. ; Chabrot, C. ; Ysebaert, I. ; Callanan, M. ; Le Gouill, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1921-6174e3e403a8c6413d51c2c9f2c1e83c0cc5af9e9212aacb4535ece38ac8e953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Geriatrics</topic><topic>Older people</topic><topic>Patients</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gressin, R.</creatorcontrib><creatorcontrib>Daguindau, N.</creatorcontrib><creatorcontrib>Tempescul, A.</creatorcontrib><creatorcontrib>Moreau, A.</creatorcontrib><creatorcontrib>Carras, S.</creatorcontrib><creatorcontrib>Cartron, G.</creatorcontrib><creatorcontrib>Schmitt, A.</creatorcontrib><creatorcontrib>Houot, R.</creatorcontrib><creatorcontrib>Dartigeas, C.</creatorcontrib><creatorcontrib>Pignon, J.</creatorcontrib><creatorcontrib>Corm, S.</creatorcontrib><creatorcontrib>Bannos, A.</creatorcontrib><creatorcontrib>Mounier, C.</creatorcontrib><creatorcontrib>Dupuis, J.</creatorcontrib><creatorcontrib>Macro, M.</creatorcontrib><creatorcontrib>Fleury, J.</creatorcontrib><creatorcontrib>Jardin, F.</creatorcontrib><creatorcontrib>Karlin, L.</creatorcontrib><creatorcontrib>Damaj, G.</creatorcontrib><creatorcontrib>Feugier, P.</creatorcontrib><creatorcontrib>Fornecker, L.</creatorcontrib><creatorcontrib>Chabrot, C.</creatorcontrib><creatorcontrib>Ysebaert, I.</creatorcontrib><creatorcontrib>Callanan, M.</creatorcontrib><creatorcontrib>Le Gouill, S.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gressin, R.</au><au>Daguindau, N.</au><au>Tempescul, A.</au><au>Moreau, A.</au><au>Carras, S.</au><au>Cartron, G.</au><au>Schmitt, A.</au><au>Houot, R.</au><au>Dartigeas, C.</au><au>Pignon, J.</au><au>Corm, S.</au><au>Bannos, A.</au><au>Mounier, C.</au><au>Dupuis, J.</au><au>Macro, M.</au><au>Fleury, J.</au><au>Jardin, F.</au><au>Karlin, L.</au><au>Damaj, G.</au><au>Feugier, P.</au><au>Fornecker, L.</au><au>Chabrot, C.</au><au>Ysebaert, I.</au><au>Callanan, M.</au><au>Le Gouill, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL</atitle><jtitle>Hematological oncology</jtitle><date>2017-06</date><risdate>2017</risdate><volume>35</volume><issue>S2</issue><spage>141</spage><epage>142</epage><pages>141-142</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.2437_131</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2017-06, Vol.35 (S2), p.141-142 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_journals_1906638434 |
| source | Access via Wiley Online Library |
| subjects | Geriatrics Older people Patients Survival |
| title | FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T13%3A24%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FIRST%20LINE%20TREATMENT%20BY%20THE%20RIBVD%20REGIMEN%20ELICITS%20HIGH%20CLINICAL%20AND%20MOLECULAR%20RESPONSE%20RATES%20AND%20PROLONGED%20SURVIVAL%20IN%20ELDERLY%20MCL%20PATIENTS;%20FINAL%20RESULTS%20OF%20a%20LYSA%20GROUP%20TRIAL&rft.jtitle=Hematological%20oncology&rft.au=Gressin,%20R.&rft.date=2017-06&rft.volume=35&rft.issue=S2&rft.spage=141&rft.epage=142&rft.pages=141-142&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.2437_131&rft_dat=%3Cproquest_cross%3E1906638434%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1906638434&rft_id=info:pmid/&rfr_iscdi=true |